The Effect of Long-Acting Beta-2 Agonist Monotherapy and Long-Acting Anticholinergic Monotherapy to Quality-of-Life in Group B Stable COPD Patients. J Respirol Indones 2022, 42 (4), 277–281. https://doi.org/10.36497/jri.v42i4.370.